Option chain shows key data for AEON Biopharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AEON Biopharma.

AEON Biopharma (AMEX:AEON) Stock, Option Chain

AEON Biopharma

AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

Oil,Refineries,And,Chemical,Plants,In,Industrial,Areas

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AEON

BLRX

NUKK

SCPX

Dow Jumps Over 300 Points; US Industrial Production Beats Estimates

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Movers

ANIP

BBAI

CFFI

DOYU

GCTK

LUXH

PMAX

QUBT

RIME

SANG

SIBN

SLXN

SOBR

SONM

TNXP

WHLR

Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

wall street ai16

Equities

BHAT

FUBO

SPRC

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma Inc

AEON CREDIT SERVICE ASIA by Aeon Credit Service Asia Company Ltd

AEON Co Ltd

AEON DELIGHT CO LTD by Aeon Delight Co., Ltd.

AEON DELIGHT Co Ltd

AEON FANTASY CO LTD by AEON Fantasy Co., Ltd.

AEON FINCL SVCS JPN ORD by Aeon Financial Services Co., Ltd.

AEON Financial Service Co Ltd

AEON Mall Co Ltd

AEON REIT INVT CORP by AEON REIT INVT CORP.

AEON REIT Investment Corp

Aeon Credit Service (Asia) Co Ltd

Investors with a lot of money to spend have taken a bearish stance on D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with QBTS, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for D-Wave Quantum.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 55%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $67,000, and 8, calls, for a total amount of $604,209.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $2.0 to $7.0 for D-Wave Quantum over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of D-Wave Quantum stands at 5986.62, with a total volume reaching 8,718.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in D-Wave Quantum, situated within the strike price corridor from $2.0 to $7.0, throughout the last 30 days.
<h3>D-Wave Quantum Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738866634_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$5.00</td>
<td>$196.9K</td>
<td>7.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.45</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$4.00</td>
<td>$172.8K</td>
<td>5.3K</td>
<td>882</td>
</tr>
<tr>
<td>QBTS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$3.4</td>
<td>$3.3</td>
<td>$3.35</td>
<td>$7.00</td>
<td>$67.0K</td>
<td>5.9K</td>
<td>212</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$3.5</td>
<td>$3.3</td>
<td>$3.3</td>
<td>$7.00</td>
<td>$49.5K</td>
<td>4.2K</td>
<td>194</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$0.5</td>
<td>$0.45</td>
<td>$0.45</td>
<td>$6.50</td>
<td>$48.6K</td>
<td>3.8K</td>
<td>2.5K</td>
</tr>
</tbody>
</table>

<h3>About D-Wave Quantum</h3>
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. The Company's mission is to unlock the power of quantum computing today to benefit business and society. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the Company's LeapTM cloud service.
In light of the recent options history for D-Wave Quantum, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of D-Wave Quantum</h3>
<ul>
<li>Trading volume stands at 44,668,138, with QBTS's price down by -3.66%, positioned at $6.03.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 49 days.</li>
</ul>
<h3>What The Experts Say On D-Wave Quantum</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $8.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Benchmark has revised its rating downward to Buy, adjusting the price target to $8. 
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on D-Wave Quantum, maintaining a target price of $9. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for D-Wave Quantum with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

QBTS

A Closer Look at D-Wave Quantum's Options Market Dynamics

Investors with a lot of money to spend have taken a bullish stance on Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Home Depot.
This isn't normal.
The overall sentiment of these big-money traders is split between 66% bullish and 13%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $362,790, and 11 are calls, for a total amount of $674,233.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $330.0 to $440.0 for Home Depot over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Home Depot's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Home Depot's whale activity within a strike price range from $330.0 to $440.0 in the last 30 days. 
<h3>Home Depot 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738866628_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$410.00</td>
<td>$258.3K</td>
<td align="right">293</td>
<td align="right">320</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$9.05</td>
<td>$8.65</td>
<td>$9.0</td>
<td>$420.00</td>
<td>$246.6K</td>
<td align="right">376</td>
<td align="right">304</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$435.00</td>
<td>$69.0K</td>
<td align="right">156</td>
<td align="right">398</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$4.95</td>
<td>$4.9</td>
<td>$4.9</td>
<td>$430.00</td>
<td>$64.1K</td>
<td align="right">181</td>
<td align="right">99</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$3.85</td>
<td>$3.65</td>
<td>$3.85</td>
<td>$435.00</td>
<td>$48.5K</td>
<td align="right">156</td>
<td align="right">127</td>
</tr>
</tbody>
</table>

<h3>About Home Depot</h3>
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The additions of the Company Store brought textiles to the lineup, and the recent tie-up with SRS will help grow professional demand in roofing, pool and landscaping projects.
Having examined the options trading patterns of Home Depot, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Home Depot</h3>
<ul>
<li>Currently trading with a volume of 602,598, the HD's price is up by 0.1%, now at $414.25. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 19 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Home Depot, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Home Depot Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on ACM Research.
Looking at options history for ACM Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 80% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $1,170,763 and 4, calls, for a total amount of $168,405.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $35.0 for ACM Research over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for ACM Research options trades today is 173.67 with a total volume of 3,946.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for ACM Research's big money trades within a strike price range of $20.0 to $35.0 over the last 30 days.
<h3>ACM Research Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738866623_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACMR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.4</td>
<td>$8.1</td>
<td>$8.11</td>
<td>$27.00</td>
<td>$406.7K</td>
<td align="right">0</td>
<td>500</td>
</tr>
<tr>
<td>ACMR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.1</td>
<td>$8.0</td>
<td>$8.1</td>
<td>$27.00</td>
<td>$405.0K</td>
<td align="right">0</td>
<td>1.0K</td>
</tr>
<tr>
<td>ACMR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.9</td>
<td>$20.00</td>
<td>$173.5K</td>
<td align="right">566</td>
<td>945</td>
</tr>
<tr>
<td>ACMR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.1</td>
<td>$3.9</td>
<td>$3.95</td>
<td>$20.00</td>
<td>$79.0K</td>
<td align="right">566</td>
<td>300</td>
</tr>
<tr>
<td>ACMR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.2</td>
<td>$3.9</td>
<td>$3.91</td>
<td>$20.00</td>
<td>$77.8K</td>
<td align="right">566</td>
<td>500</td>
</tr>
</tbody>
</table>

<h3>About ACM Research</h3>
ACM Research Inc is a United-based company. It is engaged in developing, manufacturing, and selling single-wafer wet cleaning equipment, which is used by semiconductor manufacturers in numerous manufacturing steps to remove particles, contaminants, and other random defects to improve product yield, in fabricating integrated circuits, or chips. The company offers space alternated phase shift which employs alternating phases of megasonic waves to deliver megasonic energy to flat and patterned wafer surfaces on a microscopic level; and Timely Energized Bubble Oscillation technology which provides effective, damage-free cleaning for both conventional two and three-dimensional patterned wafers at process nodes.
Following our analysis of the options activities associated with ACM Research, we pivot to a closer look at the company's own performance.
<h3>ACM Research's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,404,777, with ACMR's price up by 7.87%, positioned at $22.49.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 20 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ACM Research, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ACMR

What the Options Market Tells Us About ACM Research

In the United States, the concept of being rich is often a subject of discussion, curiosity and, sometimes, aspiration. Charles Schwab's 2024 Modern Wealth Survey provides insights into this topic, revealing that the average American equates being wealthy with a net worth of approximately $2.5 million, up from $2.2 million in 2023.
Although the most recent data from the Federal Reserve reveals the average <a href="https://www.benzinga.com/personal-finance/24/10/41585240/if-the-average-american-household-is-a-millionaire-with-a-net-worth-of-1-06-million-why-do-peopl">American household is a millionaire</a> with a net worth of $1.06 million, looking at the median or midpoint value portrays a more accurate picture. Based on the report from the Federal Reserve, the median net worth of U.S. households overall is $192,900.&nbsp;
But how spot-on are Americans&#8217; perceptions of wealth?
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
<h2 class="wp-block-heading">Wealth In America: The Numbers</h2>
• Top 2% wealth: According to Kiplinger, you'll need a net worth of $2.7 million to rank
among the top 2% of Americans in 2025.&nbsp;
• Top 5% wealth: The next tier, the top 5%, needs a net worth of around $1.17 million.
• Top 10% wealth: The top 10% of the population is estimated to have a net worth of approximately $970,900.&nbsp;
These figures illustrate a dramatic wealth gradient in the U.S., indicating a substantial increase in net worth needed to move from <a href="https://www.benzinga.com/personal-finance/24/07/39669268/are-you-rich-enough-to-join-the-top-2-heres-exactly-how-much-you-need-to-rank-among-the-wealthie">the top 10% to the top 2%</a>.
Trending: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.
<h2 class="wp-block-heading">Understanding Wealth Beyond Numbers</h2>
Wealth is not solely about the figures in your bank account or investment portfolio; it's also about how you perceive and use your resources. Here are some tips and perspectives to understand and potentially achieve wealth.
Savings and spending habits: Being able to save, that is, spending less than you earn, is a foundational aspect of accumulating wealth. Establishing responsible financial habits like budgeting and goal-setting can pave the way to wealth, regardless of the specific dollar amount.
Living below your means: In a world where consumerism is rampant, living below your means is a key principle. This might involve cutting unnecessary expenses, like reducing monthly subscriptions or dining out less frequently. Such habits not only bolster savings but also prepare you for financial emergencies. Vanguard recommends aiming to save $15,000-$30,000 in an emergency fund.&nbsp;&nbsp;
Affording desires: The ability to save and spend wisely often leads to the capacity to afford what you desire, whether it is a new vehicle or a vacation. Achieving financial goals is a strong indicator of wealth.
Trending: <a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a>
Life goals over money: Wealth is not just about accumulating money but also about fulfilling life aspirations. Whether it's running a business, becoming debt-free or saving for retirement, having a clear vision is crucial.
Preparing for retirement: A key aspect of being wealthy is <a href="https://www.benzinga.com/personal-finance/25/01/42885231/can-you-guess-what-percent-of-people-retire-with-a-3-million-nest-egg-hint-its-an-incredibly-low-number">having a solid retirement plan</a>. This involves understanding how much to save and starting early to build a financial foundation for the golden years. The retirement savings benchmark is typically 10 times your final year's salary, but of course this goal can vary significantly.&nbsp;
Money as a tool: Viewing money as a means to improve your life, rather than a source of stress, can shift your approach to wealth. Small steps like allocating extra funds toward high-interest debt can help in building a brighter financial future.
Flexibility and options: Wealth often equates to having choices — whether it's taking time off for family, investing in a business idea or learning a new skill. This flexibility is a significant indicator of wealth.
See Also: <a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a>
<h2 class="wp-block-heading">A Subjective Concept</h2>
While having a net worth of about $2.5 million is seen as the benchmark for being rich in America, it's essential to remember that wealth is a subjective concept. Healthy financial habits and personal perspectives on money are crucial in defining and achieving wealth. By focusing on smart financial planning and aligning money with personal values and goals, people can navigate their path toward what they consider to be wealthy.
<a href="https://www.benzinga.com/money/are-you-rich">Consulting a financial advisor</a> can provide tailored advice and strategies to help you achieve specific financial goals. By leveraging their expertise, you can effectively pursue your unique definition of wealth—whether that means growing your assets, securing a comfortable retirement, or reaching other financial aspirations.
Editor&#8217;s Note: Some elements of this story were previously reported by Benzinga and it has been updated to reflect current stats in 2025.&nbsp;
Read Next:
<ul>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>

Personal Finance

Are You Rich? Here's What Americans Think You Need To Be Considered Wealthy

On Thursday, Coya Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) announced blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43525603/coya-therapeutics-reports-statistically-significant-improvement-of-inflammatory-blood-markers-in-p" rel="noreferrer noopener">Alzheimer&#8217;s disease (AD)</a>.
Statistically significant reduced levels of proinflammatory markers were observed in patients receiving a five-day treatment of subcutaneous LD IL-2 on a monthly cycle in comparison to a biweekly 5-day administration or placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43094787/exclusive-coya-therapeutics-expands-its-pipeline-with-combo-therapy-for-inflammatory-diseases" rel="noreferrer noopener">EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases</a>
Lower blood levels of the proinflammatory chemokine (C-C motif) ligand 2 (CCL2) (p&lt;0.05) and proinflammatory cytokine IL-15 (p &lt;0.001) were statistically significant. A statistically significant increase in the anti-inflammatory cytokine IL-4 (p&lt;0.01) in patients receiving monthly cycles of LD IL-2 was observed compared to patients receiving a placebo.
When treatment was removed at the end of the five-month treatment period, the anti-inflammatory benefits reverted back to placebo levels.
In addition, patients receiving LD IL-2 cycles at the higher biweekly frequency showed a smaller impact on these factors than monthly LD IL-2.
Monthly LD IL-2 showed an increase in Aβ42 levels in cerebrospinal fluid (CSF), suggesting increased clearance of amyloid-β, stable levels of neurofilament light chain (NfL) in CSF, and statistically significant Treg expansion, all demonstrating targeted biological activity.
In addition, patients receiving monthly LD IL-2 showed a 4.93-point improvement in the ADAS-Cog score (Alzheimer&#8217;s cognitive scale) compared to placebo over the 21-week treatment period.
LD IL-2 was well-tolerated and no serious adverse events (SAEs) or deaths were reported. The most common AEs were mild injection site reactions and a mild increase in eosinophil counts.
In October, Coya Therapeutics&nbsp;released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41608586/coya-therapeutics-high-dose-interleukin-2-misses-the-mark-in-mid-stage-alzheimers-study" rel="noreferrer noopener">moderate Alzheimer's Disease.</a>
The study met its primary and secondary endpoints, demonstrating that treatment with low-dose interleukin-2 is safe and well-tolerated in patients with Alzheimer's.
Price Action: COYA stock is up 9.48% at $7.15 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines" target="_blank" rel="noreferrer noopener">Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines</a></li>
</ul>

Biotech

Health Care

General

COYA

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

<a href="https://www.wsj.com/health/healthcare/white-house-preparing-order-to-cut-thousands-of-federal-health-workers-bd1e0b7f?mod=latest_headlines" title="https://www.wsj.com/health/healthcare/white-house-preparing-order-to-cut-thousands-of-federal-health-workers-bd1e0b7f?mod=latest_headlines">https://www.wsj.com/health/healthcare/white-house-preparing-order-to-cut-thousands-of-federal-health-workers-bd1e0b7f?mod=latest_headlines</a>

Politics

WSJ: "White House Preparing Order to Cut Thousands of Federal Health Workers"

Thursday,&nbsp;Laboratory Corp&nbsp;(NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.39</a>.
Sales increased 9.8% year-over-year to $3.33 billion, almost in line with the consensus of $3.31 billion.
The increase was due to organic revenue growth of 5.4%, acquisitions, net of divestitures of 4%, and foreign&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43523377/labcorp-announces-2024-fourth-quarter-and-full-year-results" rel="noreferrer noopener">currency translation of 0.3%</a>.
&#8220;In 2024, Labcorp delivered exceptional results driven by both organic and inorganic growth,&#8221; said&nbsp;Adam Schechter, chairman and CEO of Labcorp&#8230;Additionally, we strengthened our presence in key high growth areas including oncology, women&#8217;s health, neurology and autoimmune disease. In 2025, we are positioned to deliver strong growth and margin expansion across both Diagnostics Laboratories and Biopharma Laboratory Services&#8230;&#8221;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
Adjusted operating income for the quarter was&nbsp;$423.2&nbsp;million, or 12.7% of revenue, compared to&nbsp;$394.9 million, or 13%, in the fourth quarter.
William Blair analyst Andrew F. Brackmann writes, &#8220;We continue to believe the underlying business at Labcorp is on solid footing, as the diagnostics segment benefits from favorable macro tailwinds and the BLS segment sees solid growth in central labs (albeit decelerating off tough comps) and early development returns to growth.&#8221;
This positions the stock well for 2025, with stable guidance and potential for gains if the company&#8217;s momentum continues.
William Blair reiterates the Outperform rating.
Guidance: LabCorp expects 2025 adjusted EPS of 15.60-$16.40 versus the consensus of $16.0. It expects 2025 sales of $13.9 billion-$14.1 billion versus consensus Of $13.8 billion.
The guidance includes 2025 Diagnostics Laboratories sales growth of 6.5%- 7.7% and Biopharma Laboratory Services&nbsp;sales growth of 3.0%- 5.0%.
Price Action:&nbsp;Laboratory stock is down 0.92% at $247.68 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43523277/volkswagen-unveils-plan-for-e20000-entry-level-electric-car" target="_blank" rel="noreferrer noopener">Volkswagen Unveils Plan For Entry-Level, $20K ID Electric Car: Details</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Analyst Color

Earnings

Guidance

Analyst Ratings

Laboratory Corporation Of America Holdings

Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook

Macro Economic Events

Global

Economics

US Treasury Secretary Bessent Says I See China Eating Some Tariffs No Matter The Level

White House Press Secretary Says More Than 40,000 Federal Employees Have Accepted Buyouts

Agilent Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) short percent of float has risen 13.04% since its last report. The company recently reported that it has 3.29 million shares sold short, which is 1.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Agilent Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738865723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Agilent Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Agilent Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Agilent Technologies's peer group average for short interest as a percentage of float is 5.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Agilent Technologies's Recent Short Interest

McDonald's's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) short percent of float has risen 3.05% since its last report. The company recently reported that it has 9.67 million shares sold short, which is 1.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.25 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>McDonald's Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738865718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for McDonald's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing McDonald's's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, McDonald's's peer group average for short interest as a percentage of float is 9.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About McDonald's?

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) short percent of float has risen 4.41% since its last report. The company recently reported that it has 17.20 million shares sold short, which is 0.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Johnson &amp; Johnson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738865712_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson &amp; Johnson has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Johnson &amp; Johnson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Johnson &amp; Johnson's peer group average for short interest as a percentage of float is 4.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(JNJ) - Analyzing Johnson & Johnson's Short Interest

A federal judge on Thursday restricted the handling of sensitive Department of Treasury data amid concerns over access granted to allies of Elon Musk leading <a href="https://www.benzinga.com/topic/elon-musk">a government review.</a>
The decision follows a lawsuit filed by labor unions arguing that the Department of Government Efficiency (DOGE) led by Musk appointees could compromise financial records, The Wall Street Journal <a href="https://www.wsj.com/politics/policy/judge-approves-limits-on-sharing-treasury-data-after-musk-allies-move-in-e0a86ec0?mod=hp_lead_pos10">reports</a>.
What Happened: The ruling, issued by U.S. District Judge Colleen Kollar-Kotelly in Washington, allows two Musk associates, Tom Krause and Marko Elez, to retain access to a Treasury payment system processing financial data of millions of Americans. However, they are now limited to &#8220;read-only&#8221; privileges and are prohibited from sharing information externally, according to WSJ.
This follows a lawsuit filed Monday by AFL-CIO and other labor organizations, represented by Public Citizen, seeking to block DOGE's access to the Bureau of the Fiscal Service, citing risks of exposing social security numbers and banking details. The court's order is temporary while Kollar-Kotelly considers a broader injunction.
Also Read: <a href="https://www.benzinga.com/25/02/43534797/tesla-sales-drop-60-in-germany-are-elon-musks-politics-getting-in-the-way-of-ev-growth">Tesla Sales Drop 60% In Germany: Are Elon Musk&#8217;s Politics Getting In The Way Of EV Growth?</a>
DOGE, created under President Donald Trump's administration, was initially an advisory body but was formally integrated into the president&#8217;s Executive Office through a day-one executive order.
Musk's team has sought federal databases and spending records, drawing scrutiny from government officials and watchdog groups. The Department of Treasury confirmed Krause and Elez were given special employment status and access to financial records, though the Justice Department argued in court that neither had shared data with outside parties, including Musk, WSJ reports.
Why It Matters: The lawsuit signals growing resistance to DOGE's actions as it gains access to government agencies. According to a Wednesday report, DOGE representatives were granted access to Centers for Medicare and Medicaid Services (CMS) payment systems. Musk said on X that fraud within CMS represented &#8220;big money fraud,&#8221; aligning with DOGE's mission to <a href="https://www.benzinga.com/25/02/43516681/doge-gains-access-to-medicare-and-medicaid-systems-elon-musk-says-this-is-where-the-big-money-fraud-is-happening">cut government spending.</a>
The ruling raises concerns about transparency, as Musk's appointees push forward with their mandate to cut $1 trillion from federal expenditures. Labor unions argue that DOGE's expanding influence threatens the privacy of millions who rely on federal programs. 
While the judge's order limits immediate risks, the broader battle over DOGE's authority is ongoing.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43529306/tariffs-are-a-means-to-an-end-bessent-defends-trade-strategy-pushes-growth-plan">&#8216;Tariffs Are A Means To An End&#8217;: Bessent Defends Trade Strategy, Pushes Growth Plan</a></li>
</ul>
Photo: Shutterstock
<hr class="wp-block-separator has-alpha-channel-opacity" />

Government

Legal

Musk Allies Face Treasury Data Limits As Judge Steps In

Several analysts raised the price target on Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) following fourth-quarter 2024 <a target="_blank" href="https://www.benzinga.com/quote/fi/analyst-ratings" rel="noreferrer noopener">results reported on Wednesday.</a>
The company reported revenue of $5.25 billion, beating the&nbsp;analyst consensus estimate of $4.96 billion, and adjusted EPS of $2.51, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43501055/fiserv-q4-earnings-merchant-financial-solutions-fuel-growth-double-digit-outlook-for-2025" rel="noreferrer noopener">analyst consensus estimate of $2.48</a>.&nbsp;
Fiserv&nbsp;expects FY25&nbsp;organic revenue&nbsp;growth of 10%-12% and adjusted EPS outlook of $10.10-$10.30, representing&nbsp;growth of 15%-17% Y/Y vs. the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$10.20 consensus</a>.
Stephens analyst Charles Nabhan raised the price forecast from $255 to $270 while reaffirming an Overweight rating.
The analyst writes that the lapping of Argentina comparables and the timing of go-lives should lead to first-quarter organic growth of less than 10% and second-half growth of above 12%.
With the transitory impact of excess inflation and Dolar Turista weakening through the year, the analyst expects adjusted and organic revenue to converge through the year.
For 2025, Nabhan projects a 1.5% foreign exchange headwind and estimates FY26 adj. EPS of $12.06.
Also, Keefe, Bruyette &amp; Woods analyst Vasundhara Govil raised the price forecast from $238 to $260 while reaffirming an Outperform rating.
The analyst says that Fiserv continues to experience healthy business trends, with volume growth in line with Visa and Mastercard across SMB and Enterprise segments and momentum carrying into January.
Distribution expansion and new product rollouts are strengthening Clover, while upcoming new client wins in 2025 should drive further growth in Financial Solutions, per the analyst.
The analyst increased the FY25 EPS estimate to $10.20 (from $10.10) and FY26 EPS estimate to $11.75 (from $11.65) to reflect the quarterly beat and strong underlying growth drivers.
Moreover, KeyBanc analyst Alex Markgraff raised the price forecast from $250 to $270 while maintaining an Overweight rating.
The analyst says that Fiserv&#8217;s results were solid, with strong Clover revenue growth and above-Street FY25 guidance for adjusted revenue and EPS standing out as key positives.
Management&#8217;s commentary on the CEO transition and FY25 growth opportunities was encouraging, despite some uneven growth cadence, adds the analyst.
As a result, Markgraff raised the FY25/FY26 estimates, driven primarily by stronger Merchant Solutions growth and margin expansion.
Additionally, RBC Capital Markets analyst Daniel R. Perlin raised the price forecast from $255 to $270 while maintaining an Outperform rating.
The analyst says that FI delivered strong results, exceeding expectations, with Clover revenue up 29% year-over-year and issuing FY25 guidance that supports continued momentum.
The analyst adjusted FY25 revenue estimate to $20.5 billion (from $20.8 billion) while maintaining the adjusted EPS estimate at $10.20. Additionally, Perlin estimates FY26 of $22.2 billion in revenue and $11.80 in adjusted EPS.
Investors can gain exposure to the stock via TCW Compounders ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRW#NYSE">GRW</a>) and Global X FinTech ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FINX#NASDAQ">FINX</a>).
Price Action: FI shares are up 0.48% at $230.64 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43507132/stocks-rebound-google-eyes-worst-drop-in-a-year-gold-shatters-fresh-records-whats-driving-markets-wednesday" target="_blank" rel="noreferrer noopener">Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Price Target

Reiteration

FINX

Fiserv Fires On All Cylinders, Analysts Bump Up Price Forecasts Post Q4 Results

On Thursday,&nbsp;Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>)&nbsp;reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the Street estimates of $2.30.</a>
The orthopedic giant reported sales of $2.02 billion, up 4.3% on a reported basis (+4.9% on constant currency), beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43522914/zimmer-biomet-announces-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">consensus of $2.014 billion</a>.
Knee product sales increased 5.1% to $839.2 million, and hip product sales increased 3% (+4% on constant currency) to $520 million.
Sports Medicine products generated sales of $489.4 million, up 8% (+8.4%).
"We have committed to diversifying our portfolio outside of core orthopedics and investing in attractive, higher-growth segments. Our recently announced agreement to acquire Paragon 28 marks a bold step towards executing on our diversification ambitions; once the transaction is closed, we expect our S.E.T. business to be larger than our Hip business, and to grow at a much faster pace," said Ivan Tornos, Zimmer Biomet's President and CEO.
Operating margin improved to 19.2% from 18.3%.
Recently, Zimmer Biomet agreed to acquire Paragon 28, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNA#NASDAQ">FNA</a>) for an upfront cash payment of&nbsp;$13.00&nbsp;per share, corresponding to an equity value of approximately&nbsp;$1.1 billion&nbsp;and an enterprise value of <a target="_blank" href="https://www.benzinga.com/news/guidance/25/01/43297796/zimmer-biomet-snaps-up-paragon-28-in-1-2-billion-deal-details" rel="noreferrer noopener">approximately&nbsp;$1.2 billion</a>.
Paragon 28 shareholders will also receive a contingent value right, which entitles the holder to up to&nbsp;$1.00&nbsp;per share in cash if certain revenue milestones are achieved.
Guidance: Zimmer Biomet expects fiscal year 2025 adjusted EPS of $8.15-$8.35 versus consensus of $8.55. The company expects 2025 revenue growth of 1%-3.5%.
Price Action:&nbsp;ZBH stock is down 3.13% at $104.86 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-5-million-potential-fine-in-china" target="_blank" rel="noreferrer noopener">AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China</a></li>
</ul>

Why Is Zimmer Biomet Stock Trading Lower On Thursday?

Mizuho analyst John Baumgartner maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Outperform and raises the price target from $80 to $85.

BRBR

Mizuho Maintains Outperform on BellRing Brands, Raises Price Target to $85

WIIM

Maximus shares are trading lower after the company reported Q1 financial results and cut its FY25 revenue guidance below estimates.

JP Morgan analyst Bill Peterson reiterated an Overweight rating on the shares of Enovix Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) with a <a href="https://www.benzinga.com/quote/ENVX/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $15.00.</a>
Enovix will release financial results for the&nbsp;fourth quarter&nbsp;<a target="_blank" href="https://www.benzinga.com//node/43323466" rel="noreferrer noopener">on February 19, 2025.</a>
The analyst anticipates fourth-quarter results to meet expectations, along with positive commentary regarding customer discussions, order pipeline, and positioning in light of tariffs and geopolitical factors.
Additionally, an update on the ongoing CFO search is expected. The analyst&#8217;s forecast predicts an adjusted EBITDA loss of -$19.8 million (compared to the Street estimate of -$22.9 million and the guidance of -$19 million to -$25 million).
The stock is likely to respond favorably to announcements regarding the progress of EX-2M product development, optimization of Fab-2 in preparation for mass production in 2026, and advancements in product qualification.
The analyst recalled that management has stated if Enovix can deliver battery samples to its first customers by second-quarter 2025, they may secure an order by third-quarter 2025 for a fourth-quarter 2025 ramp in smartphone production.
The analyst also expects management to address tariff impacts, reinforcing that Enovix is well-positioned as a non-Chinese battery supplier with a diversified supply chain.
Despite the elevated short interest, it has receded from previous highs, and the analyst remains confident in Enovix&#8217;s ability to execute its plans.
This confidence is driven by strong management, transparency, and a robust demand pipeline, although the analyst recognizes the competitive risks, especially with smartphone customer qualifications not expected until well into 2025.
Enovix is strategically positioned to secure design wins and achieve substantial revenue growth in the years ahead, leveraging the performance and safety benefits of its products, said the analyst.
Although potential risks include challenges in ramping up production to meet demand and limited expansion into the EV battery market, the analyst notes Enovix is well-equipped to capture significant market share and navigate these challenges successfully.
Price Action: ENVX shares are trading higher by 4.32% at $12.07 at the last check Thursday.
Photo: Piotr Swat via Shutterstock.

ENVX

Enovix Set To Meet Q4 Expectations, Eyes Smartphone Battery Breakthrough: JP Morgan

Goldman Sachs analyst Christine Cho maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Sell and lowers the price target from $17 to $15.

Goldman Sachs Maintains Sell on Wendy's, Lowers Price Target to $15

Goldman Sachs analyst Thiago Ojea maintains Ternium (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TX#NYSE">TX</a>) with a Buy and lowers the price target from $45 to $39.

Goldman Sachs Maintains Buy on Ternium, Lowers Price Target to $39

Press Releases

AEON Biopharma Reports First Quarter 2024 Financial Results

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

IPOs

AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Comments

AEON Biopharma

AEON Biopharma (AEON) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga